STOCKHOLM -- An investigational potassium binder prevented hyperkalemia in at-risk patients with heart failure, a randomized, placebo-controlled trial showed. Through four weeks, the compound -- RLY5016 -- resulted in a drop in mean serum potassium levels from 4.69 to 4.48 mEq/L (a change of -0.22), Bertram Pitt, MD, of the University of Michigan in Ann Arbor, reported at the European Society of Cardiology congress here.
